[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 154
Citations 0
Comment & Response
February 13, 2020

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer

Author Affiliations
  • 1Division of Hematology/Oncology, Department of Internal Medicine, University of California, Irvine, Orange
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6709

To the Editor It is with my great surprise that the study by Sparano et al1 was published in JAMA Oncology. In this high-risk group of participants with breast cancer with a recurrence score of 26 to 100, the treatment was not randomized. The statistical methods for projection of clinical outcomes were also estimated. The authors used National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 data, but the trial’s prospective period was from October 1988 to March 1993, which predates the Oncotype DX recurrence score assay (Genomic Health, first available in 2003).

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words